{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:29:20Z","timestamp":1793651360194,"version":"4.5.1"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006775","name":"GE Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006775","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      In routine practice, dopamine transporter (DAT) imaging is frequently used as a diagnostic tool to support the diagnosis of Parkinson\u2019s disease or dementia with Lewy bodies. In 2008, we published a review on which medications and drugs of abuse may influence striatal [\n                      <jats:sup>123<\/jats:sup>\n                      I]I-FP-CIT binding and consequently may influence the visual read of an [\n                      <jats:sup>123<\/jats:sup>\n                      I]I-FP-CIT SPECT scan. We made recommendations on which drugs should be withdrawn before performing DAT imaging in routine practice. Here, we provide an update of the original work based on published research since 2008.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic review of literature without language restriction from January 2008 until November 2022 to evaluate the possible effects of medications and drugs of abuse, including the use of tobacco and alcohol, on striatal DAT binding in humans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The systematic literature search identified 838 unique publications, of which 44 clinical studies were selected. Using this approach, we found additional evidence to support our original recommendations as well as some new findings on potential effect of other medications on striatal DAT binding. Consequently, we updated the list of medications and drugs of abuse that may influence the visual read of [\n                      <jats:sup>123<\/jats:sup>\n                      I]I-FP-CIT SPECT scans in routine clinical practice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We expect that a timely withdrawal of these medications and drugs of abuse before DAT imaging may reduce the incidence of false-positive reporting. Nevertheless, the decision to withdraw any medication must be made by the specialist in charge of the patient\u2019s care and considering the pros and cons of doing so.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-023-06171-x","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T04:02:38Z","timestamp":1677470558000},"page":"1974-1987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6223-3454","authenticated-orcid":false,"given":"Youssef","family":"Chahid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6613-6638","authenticated-orcid":false,"given":"Zulfiqar H.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5542-0887","authenticated-orcid":false,"given":"Max","family":"Mitropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6378-7638","authenticated-orcid":false,"given":"Jan","family":"Booij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"6171_CR1","unstructured":"GE Healthcare. DaTSCAN 74 MBq\/ml solution for injection SmPC. 2021. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/2c994e7e69fb8419e7af6ffdca52a00690afb56f."},{"key":"6171_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41531-021-00185-8","volume":"7","author":"D Bega","year":"2021","unstructured":"Bega D, Kuo PH, Chalkidou A, Grzeda MT, Macmillan T, Brand C, et al. Clinical utility of DaTscan in patients with suspected Parkinsonian syndrome: a systematic review and meta-analysis. NPJ Parkinsons Dis. 2021;7:43. https:\/\/doi.org\/10.1038\/s41531-021-00185-8.","journal-title":"NPJ Parkinsons Dis"},{"key":"6171_CR3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89:88\u2013100. https:\/\/doi.org\/10.1212\/WNL.0000000000004058.","journal-title":"Neurology"},{"key":"6171_CR4","doi-asserted-by":"publisher","first-page":"27S","DOI":"10.2967\/jnumed.121.263197","volume":"63","author":"ED Wallert","year":"2022","unstructured":"Wallert ED, van de Giessen E, Knol RJJ, Beudel M, de Bie RMA, Booij J. Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders. J Nucl Med. 2022;63:27S-32S. https:\/\/doi.org\/10.2967\/jnumed.121.263197.","journal-title":"J Nucl Med"},{"key":"6171_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s00259-007-0621-0","volume":"35","author":"J Booij","year":"2008","unstructured":"Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424\u201338. https:\/\/doi.org\/10.1007\/s00259-007-0621-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6171_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00259-009-1267-x","volume":"37","author":"J Darcourt","year":"2010","unstructured":"Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443\u201350. https:\/\/doi.org\/10.1007\/s00259-009-1267-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6171_CR7","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","volume":"47","author":"S Morbelli","year":"2020","unstructured":"Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885\u2013912. https:\/\/doi.org\/10.1007\/s00259-020-04817-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6171_CR8","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2967\/jnumed.111.100784","volume":"53","author":"DS Djang","year":"2012","unstructured":"Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53:154\u201363. https:\/\/doi.org\/10.2967\/jnumed.111.100784.","journal-title":"J Nucl Med"},{"key":"6171_CR9","unstructured":"Canadian Association of Nuclear Medicine. CANM guidelines for imaging of the dopamine transport system in evaluation of movement disorders. 2020. Retrieved from https:\/\/www.canm-acmn.ca\/resources\/Documents\/Guidelines_Resources\/CANM_Guidelines_for_Dopamine_Imaging_in_Movement_Disorders__FINAL-2.pdf."},{"key":"6171_CR10","unstructured":"Dutch Society of Nuclear Medicine. NVNG guidelines for dopamine transporters and receptor scintigraphy. 2020. Retrieved from https:\/\/richtlijnendatabase.nl\/gerelateerde_documenten\/f\/17258\/Dopamine%20Transporters%20and%20Receptor%20Scintigraphy.pdf."},{"key":"6171_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"6171_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"6171_CR13","first-page":"590","volume":"33","author":"MM Goldenberg","year":"2008","unstructured":"Goldenberg MM. Medical management of Parkinson\u2019s disease. P T. 2008;33:590\u2013606.","journal-title":"P T"},{"key":"6171_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/1531-8257(199905)14:3<436::aid-mds1008>3.0.co;2-j","volume":"14","author":"RB Innis","year":"1999","unstructured":"Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, et al. Effect of treatment with L-dopa\/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT. Mov Disord. 1999;14:436\u201342. https:\/\/doi.org\/10.1002\/1531-8257(199905)14:3%3c436::aid-mds1008%3e3.0.co;2-j.","journal-title":"Mov Disord"},{"key":"6171_CR15","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1097\/00004647-200011000-00010","volume":"20","author":"E Nurmi","year":"2000","unstructured":"Nurmi E, Bergman J, Eskola O, Solin O, Hinkka SM, Sonninen P, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab. 2000;20:1604\u20139. https:\/\/doi.org\/10.1097\/00004647-200011000-00010.","journal-title":"J Cereb Blood Flow Metab"},{"key":"6171_CR16","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","volume":"287","author":"Parkinson Study G","year":"2002","unstructured":"Parkinson Study G. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653\u201361. https:\/\/doi.org\/10.1001\/jama.287.13.1653.","journal-title":"JAMA"},{"key":"6171_CR17","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1007\/s00259-005-1922-9","volume":"32","author":"O Schillaci","year":"2005","unstructured":"Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with(123)I-FP-CIT in patients with Parkinson\u2019s disease. Eur J Nucl Med Mol Imaging. 2005;32:1452\u20136. https:\/\/doi.org\/10.1007\/s00259-005-1922-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6171_CR18","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1212\/wnl.56.11.1559","volume":"56","author":"M Guttman","year":"2001","unstructured":"Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology. 2001;56:1559\u201364. https:\/\/doi.org\/10.1212\/wnl.56.11.1559.","journal-title":"Neurology"},{"key":"6171_CR19","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/1531-8257(199911)14:6<940::aid-mds1005>3.0.co;2-y","volume":"14","author":"JE Ahlskog","year":"1999","unstructured":"Ahlskog JE, Uitti RJ, O\u2019Connor MK, Maraganore DM, Matsumoto JY, Stark KF, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson\u2019s disease. Mov Disord. 1999;14:940\u20136. https:\/\/doi.org\/10.1002\/1531-8257(199911)14:6%3c940::aid-mds1005%3e3.0.co;2-y.","journal-title":"Mov Disord"},{"key":"6171_CR20","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/jnnp.74.3.294","volume":"74","author":"A Winogrodzka","year":"2003","unstructured":"Winogrodzka A, Bergmans P, Booij J, van Royen EA, Stoof JC, Wolters EC. [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2003;74:294\u20138. https:\/\/doi.org\/10.1136\/jnnp.74.3.294.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6171_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s007020070077","volume":"107","author":"W Staffen","year":"2000","unstructured":"Staffen W, Mair A, Unterrainer J, Trinka E, Ladurner G. Measuring the progression of idiopathic Parkinson\u2019s disease with [123I] beta-CIT SPECT. J Neural Transm (Vienna). 2000;107:543\u201352. https:\/\/doi.org\/10.1007\/s007020070077.","journal-title":"J Neural Transm (Vienna)"},{"key":"6171_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/syn.10192","volume":"48","author":"E Nurmi","year":"2003","unstructured":"Nurmi E, Bergman J, Eskola O, Solin O, Vahlberg T, Sonninen P, et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson\u2019s disease using [18F]CFT PET. Synapse. 2003;48:109\u201315. https:\/\/doi.org\/10.1002\/syn.10192.","journal-title":"Synapse"},{"key":"6171_CR23","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1016\/s0024-3205(01)01079-7","volume":"68","author":"JS Fowler","year":"2001","unstructured":"Fowler JS, Volkow ND, Logan J, Franceschi D, Wang GJ, MacGregor R, et al. Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Life Sci. 2001;68:2759\u201368. https:\/\/doi.org\/10.1016\/s0024-3205(01)01079-7.","journal-title":"Life Sci"},{"key":"6171_CR24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/npp.2014.214","volume":"40","author":"JS Fowler","year":"2015","unstructured":"Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, et al. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain. Neuropsychopharmacology. 2015;40:650\u20137. https:\/\/doi.org\/10.1038\/npp.2014.214.","journal-title":"Neuropsychopharmacology"},{"key":"6171_CR25","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med. 2004;351:2498\u2013508. https:\/\/doi.org\/10.1056\/NEJMoa033447.","journal-title":"N Engl J Med"},{"key":"6171_CR26","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33:1248\u201366. https:\/\/doi.org\/10.1002\/mds.27372.","journal-title":"Mov Disord"},{"key":"6171_CR27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","volume":"86","author":"HF Wang","year":"2015","unstructured":"Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson\u2019s disease, Parkinson\u2019s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86:135\u201343. https:\/\/doi.org\/10.1136\/jnnp-2014-307659.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6171_CR28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2165\/00002512-200522090-00002","volume":"22","author":"A Lees","year":"2005","unstructured":"Lees A. Alternatives to levodopa in the initial treatment of early Parkinson\u2019s disease. Drugs Aging. 2005;22:731\u201340. https:\/\/doi.org\/10.2165\/00002512-200522090-00002.","journal-title":"Drugs Aging"},{"key":"6171_CR29","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1124\/jpet.106.105312","volume":"319","author":"BK Madras","year":"2006","unstructured":"Madras BK, Fahey MA, Goulet M, Lin Z, Bendor J, Goodrich C, et al. Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. J Pharmacol Exp Ther. 2006;319:570\u201385. https:\/\/doi.org\/10.1124\/jpet.106.105312.","journal-title":"J Pharmacol Exp Ther"},{"key":"6171_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/386827a0","volume":"386","author":"ND Volkow","year":"1997","unstructured":"Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386:827\u201330. https:\/\/doi.org\/10.1038\/386827a0.","journal-title":"Nature"},{"key":"6171_CR31","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1176\/appi.ajp.158.3.377","volume":"158","author":"ND Volkow","year":"2001","unstructured":"Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158:377\u201382. https:\/\/doi.org\/10.1176\/appi.ajp.158.3.377.","journal-title":"Am J Psychiatry"},{"key":"6171_CR32","doi-asserted-by":"publisher","first-page":"8417","DOI":"10.1523\/JNEUROSCI.18-20-08417.1998","volume":"18","author":"UD McCann","year":"1998","unstructured":"McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci. 1998;18:8417\u201322.","journal-title":"J Neurosci"},{"key":"6171_CR33","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.1523\/JNEUROSCI.21-23-09414.2001","volume":"21","author":"ND Volkow","year":"2001","unstructured":"Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21:9414\u20138.","journal-title":"J Neurosci"},{"key":"6171_CR34","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1176\/appi.ajp.158.8.1206","volume":"158","author":"Y Sekine","year":"2001","unstructured":"Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 2001;158:1206\u201314. https:\/\/doi.org\/10.1176\/appi.ajp.158.8.1206.","journal-title":"Am J Psychiatry"},{"key":"6171_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.euroneuro.2006.05.002","volume":"17","author":"YH Chou","year":"2007","unstructured":"Chou YH, Huang WS, Su TP, Lu RB, Wan FJ, Fu YK. Dopamine transporters and cognitive function in methamphetamine abuser after a short abstinence: A SPECT study. Eur Neuropsychopharmacol. 2007;17:46\u201352. https:\/\/doi.org\/10.1016\/j.euroneuro.2006.05.002.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6171_CR36","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/npp.2014.301","volume":"40","author":"A Schrantee","year":"2015","unstructured":"Schrantee A, Vaclavu L, Heijtel DF, Caan MW, Gsell W, Lucassen PJ, et al. Dopaminergic system dysfunction in recreational dexamphetamine users. Neuropsychopharmacology. 2015;40:1172\u201380. https:\/\/doi.org\/10.1038\/npp.2014.301.","journal-title":"Neuropsychopharmacology"},{"key":"6171_CR37","doi-asserted-by":"publisher","first-page":"E7138","DOI":"10.1073\/pnas.1511670112","volume":"112","author":"DS Wheeler","year":"2015","unstructured":"Wheeler DS, Underhill SM, Stolz DB, Murdoch GH, Thiels E, Romero G, et al. Amphetamine activates Rho GTPase signaling to mediate dopamine transporter internalization and acute behavioral effects of amphetamine. Proc Natl Acad Sci U S A. 2015;112:E7138\u201347. https:\/\/doi.org\/10.1073\/pnas.1511670112.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6171_CR38","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1073\/pnas.110035297","volume":"97","author":"C Saunders","year":"2000","unstructured":"Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, et al. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA. 2000;97:6850\u20135. https:\/\/doi.org\/10.1073\/pnas.110035297.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6171_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2967\/jnmt.117.201558","volume":"46","author":"JA Frankl","year":"2018","unstructured":"Frankl JA, Bose S, Kuo PH. False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine. J Nucl Med Technol. 2018;46:149\u201350. https:\/\/doi.org\/10.2967\/jnmt.117.201558.","journal-title":"J Nucl Med Technol"},{"key":"6171_CR40","unstructured":"GlaxoSmithKline.\u00a0Zyban 150 mg prolonged release tablets SmPC. 2022. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/01a47029056d06d54cab821a0bb713c21437e592."},{"key":"6171_CR41","unstructured":"Aurum Pharmaceuticals. Cocaine Hydrochloride solution 10% w\/v SmPC. 2020. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/9e16505b50d5d1f73cee973292230016a777a6b1."},{"key":"6171_CR42","unstructured":"Janssen-Cilag. Concerta XL 54 mg prolonged-release tablets SmPC. 2022. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/aa59e1fc8147b15377b2589fa441cac49c934452."},{"key":"6171_CR43","unstructured":"DAWA. Modafinil 100 mg tablets SmPC. 2022. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/b6fc44a2ec2a7432e5c213bdf4e368b0d380a0bb."},{"key":"6171_CR44","unstructured":"Janssen-Cilag. HALDOL 2 mg\/ml oral solution SmPC. 2019. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/ee716d4aa4d8f0534ca7195490baa32bb7648c25."},{"key":"6171_CR45","unstructured":"Kyowa Kirin. Abstral 300 microgram sublingual tablets SmPC. 2022. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/37739b9a0d9e60315183db2da30f827987edebe7."},{"key":"6171_CR46","unstructured":"SNIGD. Codeine Phosphate 60 mg tablets SmPC. 2022. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/72b4f125ed959f8184c8cf121a5de2a9026208d7."},{"key":"6171_CR47","unstructured":"MEDICE. Amfexa 10 mg tablets SmPC. 2022. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/58f40695962a2b0a948c676afb12d13a4273df79."},{"key":"6171_CR48","unstructured":"SNIGD. Ephedrine Hydrochloride tablets BP 60mg SmPC. 2021. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/baecc90e492e7b16399ae9a15fe27682355d8b22."},{"key":"6171_CR49","unstructured":"CNX Therapeutics. Latuda 74 mg film-coated tablets SmPC Nuvigil. 2022. Retrieved from https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/82021881e083f12d7fe0662e0cee7ce3eec497ad."},{"key":"6171_CR50","unstructured":"Novartis. SmPC Focalin XR 20 mg extended-release capsules SmPC. 2019. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021802s039lbl.pdf."},{"key":"6171_CR51","unstructured":"CTS Chemical industries. Razin 15 mg capsules SmPC. 2021. Retrieved from https:\/\/www.pharmaline.co.il\/wp-content\/uploads\/2022\/01\/Razin-30.1D.pdf."},{"key":"6171_CR52","unstructured":"Recordati Rare Diseases. Desoxyn 5 mg tablets SmPC. 2019. Retrieved from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/005378s037lbl.pdf."},{"key":"6171_CR53","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.mayocp.2018.09.012","volume":"93","author":"KN Huynh","year":"2018","unstructured":"Huynh KN, Nguyen BD. False-Positive DaTscan features with methylphenidate and phentermine therapy. Mayo Clin Proc. 2018;93:1690\u20131. https:\/\/doi.org\/10.1016\/j.mayocp.2018.09.012.","journal-title":"Mayo Clin Proc"},{"key":"6171_CR54","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1176\/appi.ajp.163.3.387","volume":"163","author":"TJ Spencer","year":"2006","unstructured":"Spencer TJ, Biederman J, Ciccone PE, Madras BK, Dougherty DD, Bonab AA, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry. 2006;163:387\u201395. https:\/\/doi.org\/10.1176\/appi.ajp.163.3.387.","journal-title":"Am J Psychiatry"},{"key":"6171_CR55","first-page":"261","volume":"25","author":"TJ Spencer","year":"2010","unstructured":"Spencer TJ, Bonab AA, Dougherty DD, Martin J, McDonnell T, Fischman AJ. A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. Int J Mol Med. 2010;25:261\u20135.","journal-title":"Int J Mol Med"},{"key":"6171_CR56","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4088\/JCP.10m06393","volume":"73","author":"TJ Spencer","year":"2012","unstructured":"Spencer TJ, Bonab AA, Dougherty DD, Mirto T, Martin J, Clarke A, et al. Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane. J Clin Psychiatry. 2012;73:346\u201352. https:\/\/doi.org\/10.4088\/JCP.10m06393.","journal-title":"J Clin Psychiatry"},{"key":"6171_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1055\/s-2003-39602","volume":"34","author":"JS Vles","year":"2003","unstructured":"Vles JS, Feron FJ, Hendriksen JG, Jolles J, van Kroonenburgh MJ, Weber WE. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics. 2003;34:77\u201380. https:\/\/doi.org\/10.1055\/s-2003-39602.","journal-title":"Neuropediatrics"},{"key":"6171_CR58","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.euroneuro.2013.05.002","volume":"23","author":"CL Crunelle","year":"2013","unstructured":"Crunelle CL, van den Brink W, Veltman DJ, van Emmerik-van OK, Dom G, Schoevers RA, et al. Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence. Eur Neuropsychopharmacol. 2013;23:1714\u201323. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.05.002.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6171_CR59","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.neuroimage.2007.12.050","volume":"40","author":"CM Szobot","year":"2008","unstructured":"Szobot CM, Shih MC, Schaefer T, Junior N, Hoexter MQ, Fu YK, et al. Methylphenidate DAT binding in adolescents with Attention-Deficit\/ Hyperactivity Disorder comorbid with Substance Use Disorder\u2013a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study. Neuroimage. 2008;40:1195\u2013201. https:\/\/doi.org\/10.1016\/j.neuroimage.2007.12.050.","journal-title":"Neuroimage"},{"key":"6171_CR60","doi-asserted-by":"publisher","first-page":"804730","DOI":"10.3389\/fpsyt.2022.804730","volume":"13","author":"HC Aster","year":"2022","unstructured":"Aster HC, Romanos M, Walitza S, Gerlach M, Muhlberger A, Rizzo A, et al. Responsivity of the Striatal Dopamine System to Methylphenidate-A within-subject I-123-beta-CIT-SPECT study in male children and adolescents with attention-deficit\/hyperactivity disorder. Front Psychiatry. 2022;13:804730. https:\/\/doi.org\/10.3389\/fpsyt.2022.804730.","journal-title":"Front Psychiatry"},{"key":"6171_CR61","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1089\/neu.2019.6892","volume":"37","author":"KB Womack","year":"2020","unstructured":"Womack KB, Dubiel R, Callender L, Dunklin C, Dahdah M, Harris TS, et al. (123)I-Iofluopane Single-Photon emission computed tomography as an imaging biomarker of pre-synaptic dopaminergic system after moderate-to-severe traumatic brain injury. J Neurotrauma. 2020;37:2113\u20139. https:\/\/doi.org\/10.1089\/neu.2019.6892.","journal-title":"J Neurotrauma"},{"key":"6171_CR62","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pnpbp.2018.04.008","volume":"86","author":"AP Akay","year":"2018","unstructured":"Akay AP, Kaya GC, Kose S, Yazicioglu CE, Erkuran HO, Guney SA, et al. Genetic imaging study with [Tc-(99m)] TRODAT-1 SPECT in adolescents with ADHD using OROS-methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:294\u2013300. https:\/\/doi.org\/10.1016\/j.pnpbp.2018.04.008.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"6171_CR63","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/rlu.0000000000000307","volume":"39","author":"G Cheng","year":"2014","unstructured":"Cheng G, Morley JF. Complete and readily reversible blocking of striatal DaTscan binding by methylphenidate. Clin Nucl Med. 2014;39:211\u20133. https:\/\/doi.org\/10.1097\/rlu.0000000000000307.","journal-title":"Clin Nucl Med"},{"key":"6171_CR64","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1038\/npp.2016.28","volume":"41","author":"L Karila","year":"2016","unstructured":"Karila L, Leroy C, Dubol M, Trichard C, Mabondo A, Marill C, et al. Dopamine transporter correlates and occupancy by Modafinil in cocaine-dependent patients: a controlled study with high-resolution PET and [(11)C]-PE2I. Neuropsychopharmacology. 2016;41:2294\u2013302. https:\/\/doi.org\/10.1038\/npp.2016.28.","journal-title":"Neuropsychopharmacology"},{"key":"6171_CR65","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1017\/S1461145713001612","volume":"17","author":"W Kim","year":"2014","unstructured":"Kim W, Tateno A, Arakawa R, Sakayori T, Ikeda Y, Suzuki H, et al. In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [(1)(8)F]FE-PE2I. Int J Neuropsychopharmacol. 2014;17:697\u2013703. https:\/\/doi.org\/10.1017\/S1461145713001612.","journal-title":"Int J Neuropsychopharmacol"},{"key":"6171_CR66","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1001\/jama.2009.351","volume":"301","author":"ND Volkow","year":"2009","unstructured":"Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301:1148\u201354. https:\/\/doi.org\/10.1001\/jama.2009.351.","journal-title":"JAMA"},{"key":"6171_CR67","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/RLU.0b013e3182816500","volume":"39","author":"P Borghammer","year":"2014","unstructured":"Borghammer P, Knudsen K, Danielsen E, Ostergaard K. False-positive 123I-FP-CIT scintigraphy and suggested dopamine transporter upregulation due to chronic modafinil treatment. Clin Nucl Med. 2014;39:e87\u20138. https:\/\/doi.org\/10.1097\/RLU.0b013e3182816500.","journal-title":"Clin Nucl Med"},{"key":"6171_CR68","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.biopsych.2010.08.026","volume":"68","author":"TJ Spencer","year":"2010","unstructured":"Spencer TJ, Madras BK, Bonab AA, Dougherty DD, Clarke A, Mirto T, et al. A positron emission tomography study examining the dopaminergic activity of armodafinil in adults using [(1)(1)C]altropane and [(1)(1)C]raclopride. Biol Psychiatry. 2010;68:964\u201370. https:\/\/doi.org\/10.1016\/j.biopsych.2010.08.026.","journal-title":"Biol Psychiatry"},{"key":"6171_CR69","doi-asserted-by":"publisher","first-page":"799319","DOI":"10.3389\/fpsyt.2022.799319","volume":"13","author":"T Nogami","year":"2022","unstructured":"Nogami T, Arakawa R, Sakayori T, Ikeda Y, Okubo Y, Tateno A. Effect of DL-Methylephedrine on dopamine transporter using positron emission tomography with [(18)F]FE-PE2I. Front Psychiatry. 2022;13:799319. https:\/\/doi.org\/10.3389\/fpsyt.2022.799319.","journal-title":"Front Psychiatry"},{"key":"6171_CR70","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/(SICI)1098-2396(199808)29:4<413::AID-SYN13>3.0.CO;2-R","volume":"29","author":"KA Bergstrom","year":"1998","unstructured":"Bergstrom KA, Jolkkonen J, Kuikka JT, Akerman KK, Viinamaki H, Airaksinen O, et al. Fentanyl decreases beta-CIT binding to the dopamine transporter. Synapse. 1998;29:413\u20135. https:\/\/doi.org\/10.1002\/(SICI)1098-2396(199808)29:4%3c413::AID-SYN13%3e3.0.CO;2-R.","journal-title":"Synapse"},{"key":"6171_CR71","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.drugalcdep.2011.03.011","volume":"118","author":"H Hou","year":"2011","unstructured":"Hou H, Yin S, Jia S, Hu S, Sun T, Chen Q, et al. Decreased striatal dopamine transporters in codeine-containing cough syrup abusers. Drug Alcohol Depend. 2011;118:148\u201351. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.03.011.","journal-title":"Drug Alcohol Depend"},{"key":"6171_CR72","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00213-015-3891-4","volume":"232","author":"ER Zaaijer","year":"2015","unstructured":"Zaaijer ER, van Dijk L, de Bruin K, Goudriaan AE, Lammers LA, Koeter MW, et al. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients. Psychopharmacology. 2015;232:2597\u2013607. https:\/\/doi.org\/10.1007\/s00213-015-3891-4.","journal-title":"Psychopharmacology"},{"key":"6171_CR73","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pscychresns.2017.03.011","volume":"263","author":"S Xu","year":"2017","unstructured":"Xu S, Liu Y, Li Y, Deng Y, Yuan J, Lv R, et al. Availability of dopamine transporters in heroin-dependent subjects: A (18)F-FECNT PET imaging study. Psychiatry Res Neuroimaging. 2017;263:121\u20136. https:\/\/doi.org\/10.1016\/j.pscychresns.2017.03.011.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"6171_CR74","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1007\/s00213-015-3992-0","volume":"232","author":"S Xu","year":"2015","unstructured":"Xu S, Liu Y, Li Y, Deng Y, Huang Y, Yuan J, et al. Longitudinal changes of dopamine transporters in heroin users during abstinence. Psychopharmacology. 2015;232:3391\u2013401. https:\/\/doi.org\/10.1007\/s00213-015-3992-0.","journal-title":"Psychopharmacology"},{"key":"6171_CR75","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1176\/appi.neuropsych.19110316","volume":"32","author":"A Powell","year":"2020","unstructured":"Powell A, Ireland C, Lewis SJG. Visual hallucinations and the role of medications in Parkinson\u2019s disease: triggers, pathophysiology, and management. J Neuropsychiatry Clin Neurosci. 2020;32:334\u201343. https:\/\/doi.org\/10.1176\/appi.neuropsych.19110316.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"6171_CR76","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s0920-9964(00)00023-2","volume":"47","author":"J Lavalaye","year":"2001","unstructured":"Lavalaye J, Linszen DH, Booij J, Dingemans PM, Reneman L, Habraken JB, et al. Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr Res. 2001;47:59\u201367. https:\/\/doi.org\/10.1016\/s0920-9964(00)00023-2.","journal-title":"Schizophr Res"},{"key":"6171_CR77","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00213-006-0570-5","volume":"191","author":"JJ Mateos","year":"2007","unstructured":"Mateos JJ, Lomena F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology. 2007;191:805\u201311. https:\/\/doi.org\/10.1007\/s00213-006-0570-5.","journal-title":"Psychopharmacology"},{"key":"6171_CR78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/JCP.0000000000000632","volume":"37","author":"WH Chang","year":"2017","unstructured":"Chang WH, Chen KC, Lee IH, Chi MH, Chen PS, Yao WJ, et al. Unaltered dopamine transporter availability in drug-naive patients with schizophrenia after 6 months of antipsychotics treatment: a naturalistic study. J Clin Psychopharmacol. 2017;37:21\u20136. https:\/\/doi.org\/10.1097\/JCP.0000000000000632.","journal-title":"J Clin Psychopharmacol"},{"key":"6171_CR79","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00406-011-0269-4","volume":"262","author":"GJ Schmitt","year":"2012","unstructured":"Schmitt GJ, Dresel S, Frodl T, la Fougere C, Boerner R, Hahn K, et al. Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 2012;262:183\u201391. https:\/\/doi.org\/10.1007\/s00406-011-0269-4.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"6171_CR80","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/sj.npp.1300036","volume":"28","author":"A Kugaya","year":"2003","unstructured":"Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003;28:413\u201320. https:\/\/doi.org\/10.1038\/sj.npp.1300036.","journal-title":"Neuropsychopharmacology"},{"key":"6171_CR81","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jad.2005.08.016","volume":"89","author":"M Argyelan","year":"2005","unstructured":"Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, Janka Z, et al. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord. 2005;89:115\u201323. https:\/\/doi.org\/10.1016\/j.jad.2005.08.016.","journal-title":"J Affect Disord"},{"key":"6171_CR82","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.pscychresns.2012.06.004","volume":"211","author":"MC Hsiao","year":"2013","unstructured":"Hsiao MC, Lin KJ, Liu CY, Schatz DB. The interaction between dopamine transporter function, gender differences, and possible laterality in depression. Psychiatry Res. 2013;211:72\u20137. https:\/\/doi.org\/10.1016\/j.pscychresns.2012.06.004.","journal-title":"Psychiatry Res"},{"key":"6171_CR83","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00213-002-1166-3","volume":"163","author":"JH Meyer","year":"2002","unstructured":"Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology. 2002;163:102\u20135. https:\/\/doi.org\/10.1007\/s00213-002-1166-3.","journal-title":"Psychopharmacology"},{"key":"6171_CR84","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/s0006-3223(02)01834-6","volume":"54","author":"SM Learned-Coughlin","year":"2003","unstructured":"Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54:800\u20135. https:\/\/doi.org\/10.1016\/s0006-3223(02)01834-6.","journal-title":"Biol Psychiatry"},{"key":"6171_CR85","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/WNF.0000000000000359","volume":"42","author":"EA Honkanen","year":"2019","unstructured":"Honkanen EA, Kemppainen N, Noponen T, Seppanen M, Joutsa J, Kaasinen V. Bupropion causes misdiagnosis in brain dopamine transporter imaging for Parkinsonism. Clin Neuropharmacol. 2019;42:181\u20133. https:\/\/doi.org\/10.1097\/WNF.0000000000000359.","journal-title":"Clin Neuropharmacol"},{"key":"6171_CR86","doi-asserted-by":"publisher","first-page":"631357","DOI":"10.3389\/fpsyt.2021.631357","volume":"12","author":"I Milenkovic","year":"2021","unstructured":"Milenkovic I, Bartova L, Papageorgiou K, Kasper S, Traub-Weidinger T, Winkler D. Case Report: Bupropion Reduces the [(123)I]FP-CIT Binding to Striatal Dopamine Transporter. Front Psychiatry. 2021;12:631357. https:\/\/doi.org\/10.3389\/fpsyt.2021.631357.","journal-title":"Front Psychiatry"},{"key":"6171_CR87","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.2147\/NDT.S150912","volume":"13","author":"CH Lin","year":"2017","unstructured":"Lin CH, Lane HY. Bupropion interferes with the image diagnosis of Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2017;13:2637\u20139. https:\/\/doi.org\/10.2147\/NDT.S150912.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6171_CR88","first-page":"359","volume":"48","author":"J Booij","year":"2007","unstructured":"Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48:359\u201366.","journal-title":"J Nucl Med"},{"key":"6171_CR89","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/YIC.0b013e32835ebcd7","volume":"28","author":"CK Wu","year":"2013","unstructured":"Wu CK, Chin Chen K, See Chen P, Chiu NT, Yeh TL, Lee IH, et al. No changes in striatal dopamine transporter in antidepressant-treated patients with major depression. Int Clin Psychopharmacol. 2013;28:141\u20134. https:\/\/doi.org\/10.1097\/YIC.0b013e32835ebcd7.","journal-title":"Int Clin Psychopharmacol"},{"key":"6171_CR90","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s41398-021-01682-3","volume":"11","author":"OR Hjorth","year":"2021","unstructured":"Hjorth OR, Frick A, Gingnell M, Hoppe JM, Faria V, Hultberg S, et al. Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial. Transl Psychiatry. 2021;11:559. https:\/\/doi.org\/10.1038\/s41398-021-01682-3.","journal-title":"Transl Psychiatry"},{"key":"6171_CR91","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1055\/s-0031-1291242","volume":"42","author":"I Makkonen","year":"2011","unstructured":"Makkonen I, Kokki H, Kuikka J, Turpeinen U, Riikonen R. Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-1 in children with autism. Neuropediatrics. 2011;42:207\u20139. https:\/\/doi.org\/10.1055\/s-0031-1291242.","journal-title":"Neuropediatrics"},{"key":"6171_CR92","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2967\/jnumed.110.078337","volume":"51","author":"M Ziebell","year":"2010","unstructured":"Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med. 2010;51:1885\u201391. https:\/\/doi.org\/10.2967\/jnumed.110.078337.","journal-title":"J Nucl Med"},{"key":"6171_CR93","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.euroneuro.2014.12.010","volume":"25","author":"A Rominger","year":"2015","unstructured":"Rominger A, Cumming P, Brendel M, Xiong G, Zach C, Karch S, et al. Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123 I]beta-CIT SPECT study. Eur Neuropsychopharmacol. 2015;25:873\u201381. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.12.010.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6171_CR94","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11011-012-9280-3","volume":"27","author":"JM Warwick","year":"2012","unstructured":"Warwick JM, Carey PD, Cassimjee N, Lochner C, Hemmings S, Moolman-Smook H, et al. Dopamine transporter binding in social anxiety disorder: the effect of treatment with escitalopram. Metab Brain Dis. 2012;27:151\u20138. https:\/\/doi.org\/10.1007\/s11011-012-9280-3.","journal-title":"Metab Brain Dis"},{"key":"6171_CR95","doi-asserted-by":"publisher","unstructured":"Zoons E, Tijssen MAJ, Dreissen YEM, Smit M, Booij J. The effect of escitalopram on central serotonergic and dopaminergic systems in patients with cervical dystonia, and its relationship with clinical treatment effects: a double-blind placebo-controlled trial. Biomolecules. 2020;10. https:\/\/doi.org\/10.3390\/biom10060880.","DOI":"10.3390\/biom10060880"},{"key":"6171_CR96","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000566","author":"D Krause","year":"2022","unstructured":"Krause D, Chrobok A, Karch S, Keeser D, Manz KM, Koch W, et al. Binding potential changes of SERT in patients with depression are associated with remission: A prospective [(1)(2)(3)I]beta-CIT-SPECT study. Exp Clin Psychopharmacol. 2022. https:\/\/doi.org\/10.1037\/pha0000566.","journal-title":"Exp Clin Psychopharmacol"},{"key":"6171_CR97","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s13139-014-0286-0","volume":"48","author":"M Seo","year":"2014","unstructured":"Seo M, Oh M, Cho M, Chung SJ, Lee CS, Kim JS. The effect of SSRIs on the binding of (18)F-FP-CIT in Parkinson patients: a retrospective case control study. Nucl Med Mol Imaging. 2014;48:287\u201394. https:\/\/doi.org\/10.1007\/s13139-014-0286-0.","journal-title":"Nucl Med Mol Imaging"},{"key":"6171_CR98","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2018.05.013","volume":"391","author":"K Ikeda","year":"2018","unstructured":"Ikeda K, Yanagihashi M, Miura K, Ishikawa Y, Hirayama T, Takazawa T, et al. Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. J Neurol Sci. 2018;391:5\u20139. https:\/\/doi.org\/10.1016\/j.jns.2018.05.013.","journal-title":"J Neurol Sci"},{"key":"6171_CR99","doi-asserted-by":"publisher","first-page":"e0157602","DOI":"10.1371\/journal.pone.0157602","volume":"11","author":"DA Monti","year":"2016","unstructured":"Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Cai J, et al. N-Acetyl cysteine may support dopamine neurons in Parkinson\u2019s disease: preliminary clinical and cell line data. PLoS One. 2016;11:e0157602. https:\/\/doi.org\/10.1371\/journal.pone.0157602.","journal-title":"PLoS One"},{"key":"6171_CR100","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cpt.1548","volume":"106","author":"DA Monti","year":"2019","unstructured":"Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Bazzan AJ, et al. N-Acetyl cysteine is associated with dopaminergic improvement in Parkinson\u2019s disease. Clin Pharmacol Ther. 2019;106:884\u201390. https:\/\/doi.org\/10.1002\/cpt.1548.","journal-title":"Clin Pharmacol Ther"},{"key":"6171_CR101","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/MNM.0b013e32832cc204","volume":"30","author":"E Itti","year":"2009","unstructured":"Itti E, Villafane G, Malek Z, Brugieres P, Capacchione D, Itti L, et al. Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson\u2019s disease: an observational study. Nucl Med Commun. 2009;30:513\u20138. https:\/\/doi.org\/10.1097\/MNM.0b013e32832cc204.","journal-title":"Nucl Med Commun"},{"key":"6171_CR102","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/ane.12537","volume":"134","author":"AF Gigante","year":"2016","unstructured":"Gigante AF, Defazio G, Niccoli Asabella A, Superbo M, Ferrari C, Liuzzi D, et al. Smoking in patients with Parkinson\u2019s disease: preliminary striatal DaT-SPECT findings. Acta Neurol Scand. 2016;134:265\u201370. https:\/\/doi.org\/10.1111\/ane.12537.","journal-title":"Acta Neurol Scand"},{"key":"6171_CR103","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2191-219X-3-39","volume":"3","author":"G Thomsen","year":"2013","unstructured":"Thomsen G, Knudsen GM, Jensen PS, Ziebell M, Holst KK, Asenbaum S, et al. No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. EJNMMI Res. 2013;3:39. https:\/\/doi.org\/10.1186\/2191-219X-3-39.","journal-title":"EJNMMI Res"},{"key":"6171_CR104","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1038\/npp.2009.49","volume":"34","author":"KP Cosgrove","year":"2009","unstructured":"Cosgrove KP, Krantzler E, Frohlich EB, Stiklus S, Pittman B, Tamagnan GD, et al. Dopamine and serotonin transporter availability during acute alcohol withdrawal: effects of comorbid tobacco smoking. Neuropsychopharmacology. 2009;34:2218\u201326. https:\/\/doi.org\/10.1038\/npp.2009.49.","journal-title":"Neuropsychopharmacology"},{"key":"6171_CR105","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.euroneuro.2017.03.008","volume":"27","author":"G Addolorato","year":"2017","unstructured":"Addolorato G, Antonelli M, Cocciolillo F, Vassallo GA, Tarli C, Sestito L, et al. Deep transcranial magnetic stimulation of the dorsolateral prefrontal cortex in alcohol use disorder patients: effects on dopamine transporter availability and alcohol intake. Eur Neuropsychopharmacol. 2017;27:450\u201361. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.03.008.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6171_CR106","doi-asserted-by":"publisher","first-page":"e0131017","DOI":"10.1371\/journal.pone.0131017","volume":"10","author":"CH Yen","year":"2015","unstructured":"Yen CH, Yeh YW, Liang CS, Ho PS, Kuo SC, Huang CC, et al. Reduced dopamine transporter availability and neurocognitive deficits in male patients with alcohol dependence. PLoS One. 2015;10:e0131017. https:\/\/doi.org\/10.1371\/journal.pone.0131017.","journal-title":"PLoS One"},{"key":"6171_CR107","doi-asserted-by":"publisher","first-page":"111187","DOI":"10.1016\/j.pscychresns.2020.111187","volume":"305","author":"T Grover","year":"2020","unstructured":"Grover T, Gupta R, Arora G, Bal CS, Ambekar A, Basu Ray S, et al. Dopamine transporter availability in alcohol and opioid dependent subjects - a (99m)Tc-TRODAT-1SPECT imaging and genetic association study. Psychiatry Res Neuroimaging. 2020;305:111187. https:\/\/doi.org\/10.1016\/j.pscychresns.2020.111187.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"6171_CR108","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13550-019-0537-2","volume":"9","author":"SR Suwijn","year":"2019","unstructured":"Suwijn SR, Verschuur CVM, Slim MA, Booij J, de Bie RMA. Reliability of visual assessment by non-expert nuclear medicine physicians and appropriateness of indications of [(123)I]FP-CIT SPECT imaging by neurologists in patients with early drug-naive Parkinson\u2019s disease. EJNMMI Res. 2019;9:63. https:\/\/doi.org\/10.1186\/s13550-019-0537-2.","journal-title":"EJNMMI Res"},{"key":"6171_CR109","doi-asserted-by":"publisher","first-page":"714","DOI":"10.2967\/jnumed.112.110106","volume":"54","author":"TA Soderlund","year":"2013","unstructured":"Soderlund TA, Dickson JC, Prvulovich E, Ben-Haim S, Kemp P, Booij J, et al. Value of semiquantitative analysis for clinical reporting of 123I\u20132-beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl)nortropane SPECT studies. J Nucl Med. 2013;54:714\u201322. https:\/\/doi.org\/10.2967\/jnumed.112.110106.","journal-title":"J Nucl Med"},{"key":"6171_CR110","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.2967\/jnumed.116.189266","volume":"58","author":"J Booij","year":"2017","unstructured":"Booij J, Dubroff J, Pryma D, Yu J, Agarwal R, Lakhani P, et al. Diagnostic performance of the visual reading of (123)I-Ioflupane SPECT images with or without quantification in patients with movement disorders or dementia. J Nucl Med. 2017;58:1821\u20136. https:\/\/doi.org\/10.2967\/jnumed.116.189266.","journal-title":"J Nucl Med"},{"key":"6171_CR111","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/WNF.0000000000000198","volume":"40","author":"C Rossi","year":"2017","unstructured":"Rossi C, Genovesi D, Marzullo P, Giorgetti A, Filidei E, Corsini GU, et al. Striatal dopamine transporter modulation after rotigotine: results from a pilot single-photon emission computed tomography study in a group of early stage Parkinson disease patients. Clin Neuropharmacol. 2017;40:34\u20136. https:\/\/doi.org\/10.1097\/WNF.0000000000000198.","journal-title":"Clin Neuropharmacol"},{"key":"6171_CR112","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V","volume":"15","author":"HTS Benamer","year":"2000","unstructured":"Benamer HTS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [(123) I]-FP-CIT SPECT imaging: The [(123) I]-FP-CIT study group. Mov Disord. 2000;15:503\u201310. https:\/\/doi.org\/10.1002\/1531-8257(200005)15:3%3c503::AID-MDS1013%3e3.0.CO;2-V.","journal-title":"Mov Disord"},{"key":"6171_CR113","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","volume":"6","author":"I McKeith","year":"2007","unstructured":"McKeith I, O\u2019Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305\u201313. https:\/\/doi.org\/10.1016\/S1474-4422(07)70057-1.","journal-title":"Lancet Neurol"},{"key":"6171_CR114","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2967\/jnumed.116.182139","volume":"58","author":"M Joling","year":"2017","unstructured":"Joling M, Vriend C, van den Heuvel OA, Raijmakers P, Jones PA, Berendse HW, et al. Analysis of Extrastriatal (123)I-FP-CIT binding contributes to the differential diagnosis of parkinsonian diseases. J Nucl Med. 2017;58:1117\u201323. https:\/\/doi.org\/10.2967\/jnumed.116.182139.","journal-title":"J Nucl Med"},{"key":"6171_CR115","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-017-1684-z","volume":"133","author":"K Doppler","year":"2017","unstructured":"Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson\u2019s disease. Acta Neuropathol. 2017;133:535\u201345. https:\/\/doi.org\/10.1007\/s00401-017-1684-z.","journal-title":"Acta Neuropathol"},{"key":"6171_CR116","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1097\/MNM.0b013e3283657404","volume":"34","author":"S Nikolaus","year":"2013","unstructured":"Nikolaus S, Beu M, Hautzel H, Silva AM, Antke C, Wirrwar A, et al. Effects of L-DOPA on striatal iodine-123-FP-CIT binding and behavioral parameters in the rat. Nucl Med Commun. 2013;34:1223\u201332. https:\/\/doi.org\/10.1097\/MNM.0b013e3283657404.","journal-title":"Nucl Med Commun"},{"key":"6171_CR117","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3389\/fnbeh.2014.00431","volume":"8","author":"S Nikolaus","year":"2014","unstructured":"Nikolaus S, Beu M, De Souza Silva AM, Huston JP, Hautzel H, Chao OY, et al. Relationship between L-DOPA-induced reduction in motor and exploratory activity and degree of DAT binding in the rat. Front Behav Neurosci. 2014;8:431. https:\/\/doi.org\/10.3389\/fnbeh.2014.00431.","journal-title":"Front Behav Neurosci"},{"key":"6171_CR118","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neuroimage.2015.07.035","volume":"121","author":"ND Volkow","year":"2015","unstructured":"Volkow ND, Wang GJ, Smith L, Fowler JS, Telang F, Logan J, et al. Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release. Neuroimage. 2015;121:20\u20138. https:\/\/doi.org\/10.1016\/j.neuroimage.2015.07.035.","journal-title":"Neuroimage"},{"key":"6171_CR119","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/pnp.742","volume":"26","author":"MK Kanani","year":"2022","unstructured":"Kanani MK, Gurunathan N. Misdiagnosis of dementia with Lewy bodies due to venlafaxine. Progr Neurol Psychiatry. 2022;26:8\u201310. https:\/\/doi.org\/10.1002\/pnp.742.","journal-title":"Progr Neurol Psychiatry"},{"key":"6171_CR120","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/s0925-4927(99)00019-0","volume":"90","author":"TP Laine","year":"1999","unstructured":"Laine TP, Ahonen A, Rasanen P, Tiihonen J. Dopamine transporter availability and depressive symptoms during alcohol withdrawal. Psychiatry Res. 1999;90:153\u20137. https:\/\/doi.org\/10.1016\/s0925-4927(99)00019-0.","journal-title":"Psychiatry Res"},{"key":"6171_CR121","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/JCP.0b013e31802e0017","volume":"27","author":"Y Shang","year":"2007","unstructured":"Shang Y, Gibbs MA, Marek GJ, Stiger T, Burstein AH, Marek K, et al. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol. 2007;27:71\u20135. https:\/\/doi.org\/10.1097\/JCP.0b013e31802e0017.","journal-title":"J Clin Psychopharmacol"},{"key":"6171_CR122","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00213-014-3688-x","volume":"232","author":"M Zheng","year":"2015","unstructured":"Zheng M, Appel L, Luo F, Lane R, Burt D, Risinger R, et al. Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836. Psychopharmacology. 2015;232:529\u201340. https:\/\/doi.org\/10.1007\/s00213-014-3688-x.","journal-title":"Psychopharmacology"},{"key":"6171_CR123","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.euroneuro.2013.10.007","volume":"24","author":"L Appel","year":"2014","unstructured":"Appel L, Bergstrom M, Buus Lassen J, Langstrom B. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. Eur Neuropsychopharmacol. 2014;24:251\u201361. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.10.007.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6171_CR124","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41397-019-0122-0","volume":"20","author":"MA Malki","year":"2020","unstructured":"Malki MA, Pearson ER. Drug-drug-gene interactions and adverse drug reactions. Pharmacogenomics J. 2020;20:355\u201366. https:\/\/doi.org\/10.1038\/s41397-019-0122-0.","journal-title":"Pharmacogenomics J"},{"key":"6171_CR125","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/clpt.2010.271","volume":"89","author":"ML Reitman","year":"2011","unstructured":"Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, et al. Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89:234\u201342. https:\/\/doi.org\/10.1038\/clpt.2010.271.","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06171-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06171-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06171-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T00:05:58Z","timestamp":1684541158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06171-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":125,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["6171"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06171-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"18 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors ZHS and MM work at GE Healthcare. Author JB is a consultant of GE Healthcare and received research funding from GE Healthcare (all payments to our institution).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}